Paediatric Rheumatology, Great North Children's Hospital, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, UK; Rheumatology, Institute Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences. Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Semin Arthritis Rheum. 2018 Aug;48(1):53-60. doi: 10.1016/j.semarthrit.2017.11.002. Epub 2017 Nov 7.
To investigate early vertical growth patterns and factors associated with poor growth in a modern inception cohort of UK children with juvenile idiopathic arthritis (JIA) using data from the Childhood Arthritis Prospective Study (CAPS).
A study period of 3 years was chosen. Children included in this analysis had a physician diagnosis of JIA and had height measurements available at both baseline and at 3-years of follow-up. Height is presented as z-scores calculated using World Health Organisation growth standards for age and gender. Growth over the 3-year period was assessed using change in z-score and height velocity. Univariable and multivariable linear regressions were used to identify factors associated with height z-score at baseline and change of height z-score at 3 years.
568 patients were included; 65% female, median baseline age 7.4 years [interquartile range (IQR) 3.6, 11.2], median symptom duration at presentation 5.5 months [IQR 3.1, 11.6]. Height z-score decreased significantly from baseline to 3 years (p ≤ 0.0001); baseline median height z-score was -0.02 (IQR -0.71, 0.61), decreasing to -0.47 (IQR -1.12, 0.24) at 3 years. Growth restriction, defined as change of height z-score ≤-0.5, was observed in 39% of patients. At 3 years, higher baseline height z-score was the strongest predictor for a negative change in height z-score [-0.3 per unit of baseline height z-score (95% CI: -0.36, -0.24), p < 0.0001].
Although overall height at 3 years after initial presentation to rheumatology is within the population norm, as a cohort, children with JIA experience a reduction of growth in height over the first 3 years of disease. Late presentation to paediatric rheumatology services is associated with lower height at presentation. However, patients with the lowest height z scores at presentation were also the most likely to see an improvement at 3 years. The impact of JIA on growth patterns is important to children and families and this study provides useful new data to support informed clinical care.
通过儿童关节炎前瞻性研究(CAPS)的数据,调查英国幼年特发性关节炎(JIA)现代发病队列中儿童早期的垂直生长模式以及与生长不良相关的因素。
选择 3 年的研究期。本分析纳入的患儿有医师诊断的 JIA,并在基线和 3 年随访时均有身高测量值。身高以根据年龄和性别计算的世界卫生组织生长标准的 z 评分表示。通过 z 评分的变化和身高速度评估 3 年内的生长情况。使用单变量和多变量线性回归来确定基线时身高 z 评分和 3 年时身高 z 评分变化的相关因素。
共纳入 568 例患儿,其中 65%为女性,中位基线年龄为 7.4 岁[四分位距(IQR)3.6,11.2],中位发病时症状持续时间为 5.5 个月[IQR 3.1,11.6]。从基线到 3 年,身高 z 评分显著降低(p ≤ 0.0001);基线时身高 z 评分中位数为-0.02(IQR-0.71,0.61),3 年时降至-0.47(IQR-1.12,0.24)。39%的患儿观察到生长受限,定义为身高 z 评分变化≤-0.5。3 年时,基线身高 z 评分越高,身高 z 评分变化越差的预测性越强[-0.3 个单位的基线身高 z 评分(95%CI:-0.36,-0.24),p<0.0001]。
尽管初始就诊风湿科后 3 年的总体身高处于人群正常值范围内,但作为一个队列,JIA 患儿在疾病的头 3 年身高增长减少。延迟至儿科风湿科就诊与就诊时身高较低相关。然而,就诊时身高 z 评分最低的患者在 3 年时也最有可能得到改善。JIA 对生长模式的影响对儿童及其家庭很重要,本研究提供了有用的新数据,以支持提供有针对性的临床护理。